PERCEPTIVE ADVISORS LLC
NEW YORK, NY · CIK 1224962 · 13F filing filed 2025-08-14
SEC-registered investment adviser since 2010 · limited liability company
- Assets managed$11.8bn
- Staff49 · 28 in investment roles
- Main clients (by assets)Private funds 99%
- Private funds17 (6 hedge) · $11.7bn gross assets
- Form ADV · 2026-07-13SEC adviser record
- Legal entityPERCEPTIVE ADVISORS LLC (US)
- Kindhedge funds, private equity, venture, futures
- Others nearbyNew York, NY, Greenwich, CT, Miami Beach, FL, Sheridan, WY, Water Mill, NY
As an employer
- Offices in1 country
- Private fundshedge 6, venture capital 2, private equity 5, other private 4
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 25 |
| Greenwich, CTUnited States | 1 |
| Miami Beach, FLUnited States | 1 |
| Sheridan, WYUnited States | 1 |
| Water Mill, NYUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Options: 1 call positions ($993.0k notional), 2 put positions ($31.3m notional) – listed below, not included above.
Holdings, Q2 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| VERONA PHARMA PLC VRNA | $520.9m19.55% | Reduced -1.1m |
| ASCENDIS PHARMA A/S SPONSORED ADR | $166.4m6.24% | New |
| ARCELLX INC ACLX | $163.2m6.12% | Reduced -448.5k |
| RHYTHM PHARMACEUTICALS INC RYTM | $152.8m5.73% | Reduced -130.1k |
| NUVALENT INC COM | $104.9m3.94% | Reduced -258.8k |
| ARTIVION INC AORT | $86.9m3.26% | Unchanged |
| MEIRAGTX HLDGS PLC MGTX | $82.2m3.09% | Added +45.0k |
| INSMED INC INSM | $65.4m2.46% | Added +141.0k |
| EDGEWISE THERAPEUTICS INC EWTX | $60.8m2.28% | Reduced -1.9m |
| PROTAGONIST THERAPEUTICS INC PTGX | $59.4m2.23% | Reduced -16.8k |
| SOLID BIOSCIENCES INC SLDB | $58.0m2.18% | Unchanged |
| APOGEE THERAPEUTICS INC COM | $51.3m1.93% | Added +59.4k |
| AMYLYX PHARMACEUTICALS INC AMLX | $50.7m1.90% | Added +28.0k |
| IMMATICS N.V IMTX | $50.5m1.89% | Unchanged |
| AKERO THERAPEUTICS INC AKRO | $48.9m1.83% | Added +122.9k |
| OMADA HEALTH INC OMDA | $44.4m1.67% | New |
| AMICUS THERAPEUTICS INC FOLD | $42.5m1.59% | Reduced -14.1m |
| ROIVANT SCIENCES LTD ROIV | $37.5m1.41% | New |
| MERUS N V MRUS | $37.3m1.40% | Added +17.7k |
| SOLENO THERAPEUTICS INC SLNO | $36.1m1.35% | Reduced -1.1m |
| ASTRIA THERAPEUTICS INC CATB | $34.8m1.30% | Unchanged |
| IMMUNOVANT INC IMVT | $34.2m1.28% | Reduced -706.2k |
| NEUROCRINE BIOSCIENCES INC NBIX | $32.1m1.20% | Added +155.0k |
| PRAXIS PRECISION MEDICINES I PRAX | $31.7m1.19% | Reduced -228.0k |
| BOSTON SCIENTIFIC CORP BSX | $30.1m1.13% | Added +150.0k |
| CARIS LIFE SCIENCES INC CAI | $29.3m1.10% | New |
| INTUITIVE SURGICAL INC ISRG | $24.5m0.92% | Added +4.5k |
| ADMA BIOLOGICS INC ADMA | $23.7m0.89% | Reduced -69.8k |
| BETA BIONICS INC BBNX | $23.2m0.87% | Unchanged |
| SPYRE THERAPEUTICS INC SYRE | $22.9m0.86% | Reduced -783.8k |
| EVOLUS INC EOLS | $22.8m0.86% | Reduced -1.7m |
| CELCUITY INC CELC | $21.8m0.82% | Reduced -729.1k |
| DYNE THERAPEUTICS INC DYN | $21.4m0.80% | Reduced -66.0k |
| SIONNA THERAPEUTICS INC SION | $21.1m0.79% | Reduced -35.1k |
| AXSOME THERAPEUTICS INC AXSM | $20.7m0.78% | Reduced -156.6k |
| REPLIGEN CORP RGEN | $20.6m0.77% | Added +36.2k |
| INSULET CORP PODD | $19.0m0.71% | Reduced -11.2k |
| OUTSET MED INC OM | $16.0m0.60% | Unchanged |
| ZYMEWORKS INC ZYME | $16.0m0.60% | Reduced -589.4k |
| CYTOMX THERAPEUTICS INC CTMX | $15.9m0.60% | New |
| ALDEYRA THERAPEUTICS INC ALDX | $15.5m0.58% | Reduced -5.2m |
| CHARLES RIV LABS INTL INC CRL | $15.2m0.57% | New |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $15.1m0.57% | Reduced -1.9m |
| INHIBRX BIOSCIENCES INC INBX | $14.0m0.52% | Reduced -86.1k |
| ADAGIO MED HLDGS INC ADGM | $12.8m0.48% | Added +64.2k |
| NURIX THERAPEUTICS INC NRIX | $12.5m0.47% | Added +799.4k |
| TRAVERE THERAPEUTICS INC TVTX | $12.3m0.46% | New |
| ORCHESTRA BIOMED HLDGS INC OBIO | $12.3m0.46% | Unchanged |
| BRIGHT MINDS BIOSCIENCES INC DRUG | $11.0m0.41% | Reduced -24.0k |
| INHIBIKASE THERAPEUTICS INC IKT | $10.6m0.40% | Reduced -492.7k |
| VIKING THERAPEUTICS INC VKTX | $10.1m0.38% | Reduced -128.3k |
| ULTRAGENYX PHARMACEUTICAL IN RARE | $9.8m0.37% | New |
| KYMERA THERAPEUTICS INC KYMR | $9.2m0.34% | New |
| NAUTILUS BIOTECHNOLOGY INC NAUT | $9.1m0.34% | Unchanged |
| PENUMBRA INC PEN | $8.4m0.32% | New |
| CRESCENT BIOPHARMA INC. CBIO | $7.3m0.27% | New |
| AQUESTIVE THERAPEUTICS INC AQST | $7.3m0.27% | Reduced -1.5m |
| JANUX THERAPEUTICS INC JANX | $6.8m0.25% | Reduced -677.7k |
| ANTERIS TECHNOLOGIES GLOBAL AVR | $6.5m0.24% | Reduced -434.9k |
| XENON PHARMACEUTICALS INC XENE | $6.3m0.24% | Reduced -124.5k |
| VIRIDIAN THERAPEUTICS INC VRDN | $6.3m0.23% | Reduced -212.2k |
| CORVUS PHARMACEUTICALS INC CRVS | $5.8m0.22% | New |
| SEPTERNA INC SEPN | $5.7m0.21% | New |
| GLOBUS MED INC GMED | $5.2m0.20% | New |
| ENVVENO MEDICAL CORPORATION COM | $5.1m0.19% | New |
| HELIX ACQUISITION CORP II BBOT | $4.2m0.16% | Unchanged |
| OPUS GENETICS INC IRD | $4.1m0.15% | Unchanged |
| CONTINEUM THERAPEUTICS INC CTNM | $2.8m0.10% | Reduced -741.8k |
| LYRA THERAPEUTICS INC LYRA | $2.3m0.09% | New |
| SCPHARMACEUTICALS INC SCPH | $1.9m0.07% | Unchanged |
| ATHIRA PHARMA INC COM | $1.6m0.06% | Unchanged |
| RAPT THERAPEUTICS INC RAPT | $1.5m0.06% | New |
| TRINITY BIOTECH PLC SPONS ADR NEW | $1.2m0.04% | New |
| FORTE BIOSCIENCES INC FBRX | $881.7k0.03% | New |
| AVALO THERAPEUTICS INC AVTX | $696.9k0.03% | Reduced -380.3k |
| BIODESIX INC COM | $613.0k0.02% | Unchanged |
| LEXEO THERAPEUTICS INC LXEO | $562.1k0.02% | Unchanged |
| APYX MEDICAL CORPORATION APYX | $337.5k0.01% | Unchanged |
| KALA BIO INC COM NEW | $262.9k0.01% | Reduced -222.4k |
| ENSYSCE BIOSCIENCES INC ENSC | $193.3k0.01% | Unchanged |
| REVOLUTION MEDICINES INC RVMDW | $65.7k0.00% | Unchanged |
| SURROZEN INC *W EXP 08/01/203 | $3.0k0.00% | Unchanged |
Sold out since Q1 2025
| Security | Value then |
|---|---|
| INTRA-CELLULAR THERAPIES INC ITCI | $103.7m786.4k shares |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $42.3m12.7m shares |
| ARGENX SE ARGX | $35.2m59.5k shares |
| VAXCYTE INC PCVX | $26.7m706.6k shares |
| MADRIGAL PHARMACEUTICALS INC MDGL | $15.4m46.5k shares |
| DEXCOM INC DXCM | $12.2m178.0k shares |
| ACRIVON THERAPEUTICS INC ACRV | $10.9m5.4m shares |
| CARGO THERAPEUTICS INC | $9.9m2.4m shares |
| EYEPOINT PHARMACEUTICALS INC EYPT | $8.3m1.5m shares |
| DISC MEDICINE INC IRON | $7.4m150.0k shares |
| ADAPTIVE BIOTECHNOLOGIES COR ADPT | $6.9m931.0k shares |
| OCULAR THERAPEUTIX INC OCUL | $6.7m915.8k shares |
| DELCATH SYS INC DCTH | $5.9m462.4k shares |
| RAPT THERAPEUTICS INC | $5.4m4.4m shares |
| KESTRA MED TECHNOLOGIES LTD KMTS | $5.0m200.0k shares |
| ONKURE THERAPEUTICS INC OKUR | $4.3m1.0m shares |
| MEREO BIOPHARMA GROUP PLC MREO | $2.0m877.0k shares |
| LYRA THERAPEUTICS INC LYRA | $1.6m12.8m shares |
| TRAWS PHARMA INC TRAW | $970.1k421.8k shares |
| ROCKET PHARMACEUTICALS INC RCKT | $938.6k140.7k shares |
| CULLINAN THERAPEUTICS INC CGEM | $606.4k80.1k shares |
| APPLIED THERAPEUTICS INC APLT | $420.5k860.0k shares |
| NANOBIOTIX NBTX | $376.1k105.1k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $24.9m300.0k shares | New |
| CAPRICOR THERAPEUTICS INC CAPR · Put | $6.5m650.0k shares | New |
| CAPRICOR THERAPEUTICS INC CAPR · Call | $993.0k100.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 38.
| Company | Stake |
|---|---|
| ADAGIO MED HLDGS INC ADGM · 13G · filed 2026-05-15 | 55.4%≈ $8.8m |
| LEONABIO INC LONA · 13D · filed 2026-10-26 | 20.0%≈ $17.4m |
| LYRA THERAPEUTICS INC LYRA · 13D · filed 2025-08-14 | 15.6% |
| MEIRAGTX HLDGS PLC MGTX · 13D · filed 2026-04-24 | 12.6%≈ $158.6m |
| SOLID BIOSCIENCES INC SLDB · 13D · filed 2026-08-14 | 11.2%≈ $120.3m |
| PERCEPTIVE CAP SOLUTIONS COR FRNM · 13G · filed 2026-07-23 | 10.1% |
| INHIBRX BIOSCIENCES INC INBX · 13G · filed 2026-08-14 | 10.0%≈ $141.1m |
| ALTO NEUROSCIENCE INC ANRO · 13G · filed 2026-08-14 | 10.0%≈ $110.2m |
| OPUS GENETICS INC IRD · 13G · filed 2026-08-14 | 10.0%≈ $37.6m |
| ENGENE HOLDINGS INC 13G · filed 2026-08-14 | 10.0% |
| KIORA PHARMACEUTICALS INC KPRX · 13G · filed 2026-08-10 | 10.0%≈ $1.2m |
| ENVVENO MEDICAL CORPORATION 13G · filed 2026-02-17 | 10.0% |
| ORCHESTRA BIOMED HLDGS INC OBIO · 13G · filed 2025-11-14 | 10.0%≈ $24.5m |
| TRINITY BIOTECH PLC 13D · filed 2026-05-04 | 9.9% |
| OUTSET MED INC OM · 13G · filed 2025-02-28 | 9.5% |
| NAUTILUS BIOTECHNOLOGY INC NAUT · 13D · filed 2026-08-14 | 9.1%≈ $21.8m |
| KARDIGAN INC KARD · 13D · filed 2026-10-01 | 8.8%≈ $196.9m |
| QUINCE THERAPEUTICS INC IRLA · 13G · filed 2026-10-14 | 8.4%≈ $1.7m |
| RESEARCH ALLIANCE CORP III RACC · 13G · filed 2026-05-28 | 8.2%≈ $8.0m |
| X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 | 8.1%≈ $37.8m |
| SUTRO BIOPHARMA INC STRO · 13G · filed 2026-08-14 | 7.9%≈ $43.3m |
| PALISADE BIO INC PALI · 13G · filed 2026-05-15 | 7.9%≈ $29.5m |
| IMMATICS N.V IMTX · 13D · filed 2026-08-27 | 7.6%≈ $113.5m |
| AMYLYX PHARMACEUTICALS INC AMLX · 13G · filed 2026-05-15 | 7.5%≈ $148.8m |
| SAB BIOTHERAPEUTICS INC SABS · 13G · filed 2026-08-14 | 7.3%≈ $25.8m |
Trades reported as a company insider in Q2 2025
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2025-05-01 | ACRIVON THERAPEUTICS INC 10% owner · See Footnote | Sold | $400.5k298.9k shares |
| 2025-04-30 | ACRIVON THERAPEUTICS INC 10% owner · See Footnote | Sold | $617.4k437.9k shares |
| 2025-04-29 | ACRIVON THERAPEUTICS INC 10% owner · See Footnote | Sold | $352.5k250.0k shares |
| 2025-04-28 | ACRIVON THERAPEUTICS INC 10% owner · See Footnote | Sold | $335.8k215.3k shares |
| 2025-04-25 | ACRIVON THERAPEUTICS INC 10% owner · See Footnote | Sold | $2.1m1.1m shares |
| 2025-04-03 | ALDEYRA THERAPEUTICS INC 10% owner · See Footnote | Sold | $4.8m3.4m shares |